The effect of an elemental diet on oral mucositis of esophageal cancer patients treated with DCF chemotherapy: a multi-center prospective feasibility study (EPOC study)

• Published in: Esophagus : official journal of the Japan Esophageal Society Vol. 15; no. 4; pp. 239 - 248
• Main Authors: Tanaka, Yoshihiro, Ueno, Takao, Yoshida, Naoya, Akutsu, Yasunori, Takeuchi, Hiroya, Baba, Hideo, Matsubara, Hisahiro, Kitagawa, Yuko, Yoshida, Kazuhiro
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.10.2018; Springer Nature B.V
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Chemotherapy; Esophageal cancer; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - pathology; Esophagus; Feasibility Studies; Female; Food, Formulated - standards; Food, Formulated - statistics & numerical data; Gastroenterology; Humans; Incidence; Male; Medical diagnosis; Medication Adherence - statistics & numerical data; Medicine; Medicine & Public Health; Middle Aged; Mucositis; Neoplasm Staging; Original; Original Article; Prospective Studies; Stomatitis - chemically induced; Stomatitis - diet therapy; Stomatitis - epidemiology; Stomatitis - prevention & control; Surgical Oncology; Thoracic Surgery; Esophageal carcinoma; Chemotherapy; Central review system; Oral mucositis; DCF
• ISSN: 1612-9059; 1612-9067
• DOI: 10.1007/s10388-018-0620-1

Purpose Oral mucositis (OM) is one of the most uncomfortable adverse events experienced by cancer patients undergoing chemotherapy. Previous reports have revealed that the oral administration of an elemental diet (ED) may prevent OM. However, the incidence of OM has not been accurately determined by specialized diagnostic methods and the effects of an ED on OM remain unclear. We investigated the dose that could feasibly be administered and its effects with regard to the suppression of OM in esophageal cancer patients undergoing chemotherapy. Methods We performed a prospective multi-center feasibility study of the administration of an ED (160 g/day) with 2 cycles of docetaxel/cisplatin/5-FU (DCF) chemotherapy. We assessed compliance to the ED for 49 days and the incidence of OM according to the amount of the ED that was orally administered. The incidence of OM was graded by a dental specialist who was experienced in dental oncology using a central OM review system. Results Fourteen of 20 patients (70%) were able to complete the orally administered ED (160 g/day) during the course of chemotherapy. Three patients (15%) could not take the ED orally for 9, 14, and 21 days, respectively, while 1 patient (5%) took the ED orally at an average dose of 80 g/day for 35 days. The remaining 2 patients (10%) could not take the 80 g/day dose for 11 and 12 days, respectively. The incidence of grade ≥ 2 OM in the ED completion group (15.4%, 2 of 13 patients) was significantly lower than that in the non-completion group (66.7%, 4 of 6 patients) ( p  = 0.046). Conclusions An ED might be a one of the test treatment to reduce the incidence of OM in esophageal cancer patients treated with DCF and should be evaluated in further randomized study. Clinical trial The date of submission: Dec 08th, 2017.